News Articles and Montana BioScience Alliance Newsletters
The University of Montana in Missoula and Montana State University in Bozeman have achieved “R1” designations for their research programs. The “R1” classification is conferred by the Carnegie Classification of Institutions of Higher Education organization based on factors including research expenditures, staffing, and number of doctorates awarded.
Montana State University Billings announces the launch of the Institute for Neurodiversity and Applied Behavior Analysis at the Montana Center for Inclusive Education (MCIE) on university campus. The Institute will serve children in the region with mental, social, and behavioral differences associated with autism spectrum disorders, developmental disabilities, similar mental health disorders, and other behavioral disabilities, by providing direct and telehealth clinical support.
BioScience Laboratories, a Nelson Labs company located in Bozeman, MT, and a leader in topical antimicrobial-product testing in the consumer, pharmaceutical, and medical-device industries, operates a biosafety-level-3 (BSL-3) laboratory that was inspected by the Centers for Disease Control and Prevention (CDC) last year. The CDC has since confirmed that the Bozeman facility’s BSL-3 lab and related procedures adequately meet guidelines for the company to test all common and concerning strains of SARS-CoV-2 and other potentially dangerous pathogens.
Last year, the World Trade Organization (WTO) proposed that biotechnology companies, including some in Montana, be required to give their formulas for COVID-19 vaccines to countries that aren’t as advanced as the U.S. in developing these technologies. The Biden administration has supported this proposal, but we have deep concerns about it.
The immuno-oncology market has grown at a compound rate of 10%, from $57 billion to $69 billion in 2021. It is expected to reach around $98 billion by 2025. This is a highly competitive market, so companies in this sector have to innovate rapidly by creating novel drugs and therapies. Montana’s Inimmune recently made the top-20 list.
When her husband was undergoing cancer treatment, Cindy Perez of Southwest Ranches, Fla., learned about a new blood test that could help find early cancers. The 50-year-old said she felt fine, but her husband urged her to take the test anyway.
Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.
As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year.
Administrative Supplements to Promote Diversity in Research and Development Small Businesses – SBIR/STTR
Contract Pre-solicitation for R&D that will contribute toward ARPA-H mission needs and SBIR program objectives.
View the September 2024 Newsletter now!
View the Summer 2024 Newsletter now!